Home › Kanser sa Baga › Texas › San Antonio
Pag-aaral pangklinika para sa Kanser sa Baga sa San Antonio, TX
26 pag-aaral para sa Kanser sa Baga ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng San Antonio (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study of ZW251 in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1
- START San Antonio, San Antonio
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Nagre-recruitPhase 1/2
- New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Audie L Murphy VA Hospital, San Antonio
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Nagre-recruitPhase 1
- University of Texas San Antonio (UTSA), San Antonio
A Study of PHN-012 in Patients With Advanced Solid Tumors
Nagre-recruitPhase 1
- PHN-012-001 Site, San Antonio
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Nagre-recruitPhase 2/3
- Local Institution - 0173, San Antonio
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Nagre-recruitPhase 1/2
- NEXT Oncology San Antonio, San Antonio
- START Texas, San Antonio
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Nagre-recruitPhase 1
- NEXT, San Antonio
- START - San Antonio, San Antonio
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Nagre-recruitPhase 1/2
- START San Antonio, San Antonio
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Nagre-recruitPhase 1
- START - San Antonio, San Antonio
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Nagre-recruitPhase 1/2
- Avenzo Therapeutics Recruiting Site, San Antonio
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nagre-recruitPhase 1
- START San Antonio, San Antonio
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- UT Health Mays Cancer Center, San Antonio
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1
- START - San Antonio, San Antonio
IDOV-Immune for Advanced Solid Tumors
Nagre-recruitPhase 1
- South Texas Accelerated Research Therapeutics, San Antonio
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
Nagre-recruit
- Audie Murphy VA Medical Center, San Antonio
- Brooke Army Medical Center, San Antonio
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Nagre-recruitPhase 1/2
- Mays Cancer Center / University of Texas, San Antonio, San Antonio
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Nagre-recruitPhase 1
- NEXT Oncology, San Antonio
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Nagre-recruitPhase 1
- Research Site #2, San Antonio
- Research Site, San Antonio
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Nagre-recruitPhase 1
- START, San Antonio
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Nagre-recruitPhase 1/2
- NEXT Oncology, San Antonio
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Nagre-recruitPhase 1/2
- Next Oncology, San Antonio
Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer
Nagre-recruitObservasyonal na pag-aaral
- UT Health San Antonio, M.D. Anderson Cancer Center, San Antonio
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Nagre-recruitPhase 1/2
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
- UT Health San Antonio, San Antonio
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Nagre-recruitPhase 1/2
- Next Oncology, San Antonio, San Antonio
Collection of Sputum and Labeling for Lung Cancer
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- South Texas Veterans Health Care System (STVHCS)/Audie L. Murphy Memorial Veterans Hospital, San Antonio
Pag-aaral para sa Kanser sa Baga sa ibang lungsod
- Houston, TX78 pag-aaral
- Boston, MA62 pag-aaral
- New York City, NY60 pag-aaral
- Los Angeles, CA45 pag-aaral
- Arlington, VA41 pag-aaral
- Washington, DC41 pag-aaral
- Chicago, IL41 pag-aaral
- Nashville, TN40 pag-aaral
- Baltimore, MD40 pag-aaral
- St. Louis, MO39 pag-aaral
- Columbus, OH37 pag-aaral
- Philadelphia, PA36 pag-aaral
Iba pang pag-aaral sa San Antonio
- Non-Small Cell Lung Cancer59 pag-aaral
- Kanser sa Suso47 pag-aaral
- Colorectal Cancer46 pag-aaral
- Metastatic Cancer44 pag-aaral
- Kanser (lahat ng uri)41 pag-aaral
- Obesity40 pag-aaral
- Type 2 Diabetes37 pag-aaral
- Overweight34 pag-aaral
- Kanser sa Ovary31 pag-aaral
- Kanser sa Pancreas31 pag-aaral
- Kanser sa Prostate28 pag-aaral
- Kanser ng Endometrium27 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.